BR112019000257A2 - polipeptídeos solúveis do receptor 3 do fator de crescimento de fibroblastos (sfgfr3) e usos dos mesmos - Google Patents

polipeptídeos solúveis do receptor 3 do fator de crescimento de fibroblastos (sfgfr3) e usos dos mesmos

Info

Publication number
BR112019000257A2
BR112019000257A2 BR112019000257A BR112019000257A BR112019000257A2 BR 112019000257 A2 BR112019000257 A2 BR 112019000257A2 BR 112019000257 A BR112019000257 A BR 112019000257A BR 112019000257 A BR112019000257 A BR 112019000257A BR 112019000257 A2 BR112019000257 A2 BR 112019000257A2
Authority
BR
Brazil
Prior art keywords
sfgfr3
polypeptides
growth factor
factor receptor
fibroblast growth
Prior art date
Application number
BR112019000257A
Other languages
English (en)
Portuguese (pt)
Inventor
Gouze Elvire
Garcia Stéphanie
Original Assignee
Inst Nat Sante Rech Med
Therachon Sas
Univ Nice Sophia Antipolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Therachon Sas, Univ Nice Sophia Antipolis filed Critical Inst Nat Sante Rech Med
Publication of BR112019000257A2 publication Critical patent/BR112019000257A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112019000257A 2016-07-07 2017-07-07 polipeptídeos solúveis do receptor 3 do fator de crescimento de fibroblastos (sfgfr3) e usos dos mesmos BR112019000257A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US201762467478P 2017-03-06 2017-03-06
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BR112019000257A2 true BR112019000257A2 (pt) 2019-10-01

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000257A BR112019000257A2 (pt) 2016-07-07 2017-07-07 polipeptídeos solúveis do receptor 3 do fator de crescimento de fibroblastos (sfgfr3) e usos dos mesmos

Country Status (20)

Country Link
US (3) US10294289B2 (https=)
EP (2) EP3481859B1 (https=)
JP (2) JP7046903B2 (https=)
KR (2) KR20220122762A (https=)
CN (1) CN109715658B (https=)
AU (2) AU2017294551B2 (https=)
BR (1) BR112019000257A2 (https=)
CA (1) CA3029877C (https=)
DK (1) DK3481859T3 (https=)
ES (1) ES2912559T3 (https=)
HU (1) HUE058734T2 (https=)
IL (1) IL264030A (https=)
MX (1) MX2018016257A (https=)
PL (1) PL3481859T3 (https=)
PT (1) PT3481859T (https=)
RU (1) RU2751483C2 (https=)
SG (1) SG11201900074WA (https=)
SI (1) SI3481859T1 (https=)
WO (1) WO2018007597A1 (https=)
ZA (1) ZA201900507B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PT3481859T (pt) 2016-07-07 2022-05-23 Pfizer Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos
JP7335247B2 (ja) * 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
US12390510B2 (en) 2019-05-29 2025-08-19 Massachusetts Eye And Ear Infirmary Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DE69619526T2 (de) 1995-06-12 2002-10-31 Yeda Research And Development Co., Ltd. Fgf9 als spezifischer ligand für fgfr3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CA2432257A1 (en) 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2558758C (en) 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗ｆｇｆｒ３抗體及使用方法
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
BR112012016992A2 (pt) 2010-01-14 2019-09-24 Univ Yale "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CN104797936B (zh) 2012-07-24 2017-11-24 纽约市哥伦比亚大学理事会 融合蛋白及其方法
CA2878183A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US20180148494A1 (en) 2015-01-07 2018-05-31 TheAchon Soluble fgfr3 decoys for treating skeletal growth disorders
PT3481859T (pt) 2016-07-07 2022-05-23 Pfizer Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos
JP7335247B2 (ja) 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置

Also Published As

Publication number Publication date
PL3481859T3 (pl) 2022-07-11
WO2018007597A1 (en) 2018-01-11
RU2019100381A (ru) 2020-08-11
AU2022202906A1 (en) 2022-05-26
ES2912559T3 (es) 2022-05-26
CA3029877A1 (en) 2018-01-11
SG11201900074WA (en) 2019-02-27
HUE058734T2 (hu) 2022-09-28
ZA201900507B (en) 2023-04-26
JP7348980B2 (ja) 2023-09-21
SI3481859T1 (sl) 2022-07-29
EP3481859A1 (en) 2019-05-15
RU2751483C2 (ru) 2021-07-14
JP2022096660A (ja) 2022-06-29
MX2018016257A (es) 2019-11-21
KR102432192B1 (ko) 2022-08-12
US20210309718A1 (en) 2021-10-07
CN109715658A (zh) 2019-05-03
US20180230197A1 (en) 2018-08-16
US10294289B2 (en) 2019-05-21
PT3481859T (pt) 2022-05-23
KR20190037240A (ko) 2019-04-05
AU2017294551A1 (en) 2019-01-31
CA3029877C (en) 2023-07-25
RU2019100381A3 (https=) 2020-11-23
US11021528B2 (en) 2021-06-01
US11697678B2 (en) 2023-07-11
EP4122955A1 (en) 2023-01-25
AU2017294551B2 (en) 2022-03-03
IL264030A (en) 2019-01-31
CN109715658B (zh) 2023-09-12
DK3481859T3 (da) 2022-04-25
JP7046903B2 (ja) 2022-04-04
JP2019527053A (ja) 2019-09-26
KR20220122762A (ko) 2022-09-02
US20200190162A1 (en) 2020-06-18
EP3481859B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
BR112019000257A2 (pt) polipeptídeos solúveis do receptor 3 do fator de crescimento de fibroblastos (sfgfr3) e usos dos mesmos
MX2018014154A (es) Polinucleotidos moduladores.
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
CL2016001895A1 (es) Compuestos
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
CL2018003087A1 (es) Síntesis de indazoles.
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
BR112017018940A2 (pt) anticorpos sítio-específicos projetados e métodos de uso
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX390126B (es) Nuevas isoformas de tripsina y su uso.
HUE049556T2 (hu) Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásra
UY36602A (es) Variantes de protoxina-ii y métodos de uso

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) ; THERACHON SAS (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR)

B25A Requested transfer of rights approved

Owner name: UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; THERACHON HOLDING GMBH (CH)

B25A Requested transfer of rights approved

Owner name: UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; PFIZER INC. (US)

B25G Requested change of headquarter approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; PFIZER INC. (US) ; UNIVERSITE NICE SOPHIA ANTIPOLIS (FR)

B25A Requested transfer of rights approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; PFIZER INC. (US) ; UNIVERSITE COTE D'AZUR (FR)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; PFIZER INC. (US) ; UNIVERSITE COTE D'AZUR (FR)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2840 DE 10/06/2025.